Semaglutide for weight loss in short supply
Click Here to Manage Email Alerts
Novo Nordisk announced it cannot meet demand in the U.S. for its recently approved weight-loss drug semaglutide for at least the first half of 2022.
A contractor filling syringes for Wegovy pens cannot comply with Good Manufacturing Practices and has halted manufacturing and deliveries, according to a company press release. Novo Nordisk says it expects to meet U.S. demand later in 2022 and recommends directing available supplies of the drug to patients already using semaglutide rather than initiating new patients.
As Healio previously reported, once-weekly semaglutide injection was approved in June for chronic weight management in adults with obesity or with overweight and at least one weight-related condition. The STEP clinical trial program demonstrated substantial long-term weight loss with the drug.
“The thing that is most exciting about the semaglutide data is this is the beginning of a potentially new era in how we think about what pharmacotherapy can do — and can do safely — with achieving larger volume weight loss,” Jamy D. Ard, MD, professor of epidemiology and prevention and co-director of the Weight Management Center at the Wake Forest School of Medicine and Endocrine Today Editorial Board Member, told Healio in August.
Collapse
Press release
Read more about
Click Here to Manage Email Alerts